A probabilistic knowledge graph for target identification
Fig 5
In-vitro validation of the target candidates predicted by Progeni for melanoma.
(A), CCK-8 assays of the B16F10 cells with shRNA knockdown after 36h culture. (B)-(D), Survival curves of the metastatic or primary melanoma patients from The Cancer Genome Atlas (TCGA) with high or low expression of genes HSP90AB1 (n = 176, metastatic melanoma, (B)), MME (n = 173, metastatic melanoma, (C)), and RPS6KB1 (n = 50, primary melanoma, (D)), respectively. The patients with the 25% highest gene expression were defined as “High,” while the lowest 25% were defined as “Low.” (E)-(F), CCK-8 assays of the B16F10 cells after 48h treatment with the HSP90AB1 inhibitors tanespimycin (E) or SNX-5422 (F), whose molecular structures and half maximal inhibitory concentration (IC50) values are also shown.